216 related articles for article (PubMed ID: 33037919)
1. Pharmacokinetics of alemtuzumab in pediatric patients undergoing ex vivo T-cell-depleted haploidentical hematopoietic cell transplantation.
Bhoopalan SV; Cross SJ; Panetta JC; Triplett BM
Cancer Chemother Pharmacol; 2020 Dec; 86(6):711-717. PubMed ID: 33037919
[TBL] [Abstract][Full Text] [Related]
2. Pretransplant Absolute Lymphocyte Counts Impact the Pharmacokinetics of Alemtuzumab.
Marsh RA; Fukuda T; Emoto C; Neumeier L; Khandelwal P; Chandra S; Teusink-Cross A; Vinks AA; Mehta PA
Biol Blood Marrow Transplant; 2017 Apr; 23(4):635-641. PubMed ID: 28089878
[TBL] [Abstract][Full Text] [Related]
3. Immune Modulation Properties of Zoledronic Acid on TcRγδ T-Lymphocytes After TcRαβ/CD19-Depleted Haploidentical Stem Cell Transplantation: An analysis on 46 Pediatric Patients Affected by Acute Leukemia.
Merli P; Algeri M; Galaverna F; Milano GM; Bertaina V; Biagini S; Girolami E; Palumbo G; Sinibaldi M; Becilli M; Leone G; Boccieri E; Grapulin L; Gaspari S; Airoldi I; Strocchio L; Pagliara D; Locatelli F
Front Immunol; 2020; 11():699. PubMed ID: 32477328
[TBL] [Abstract][Full Text] [Related]
4. Impact of alemtuzumab pharmacokinetics on T-cell dynamics, graft-versus-host disease and viral reactivation in patients receiving allogeneic stem cell transplantation with an alemtuzumab-based T-cell-depleted graft.
Loeff FC; van Egmond EHM; Moes DJAR; Wijnands C; Von Dem Borne PA; Veelken H; Falkenburg JHF; Jedema I; Halkes CJM
Transpl Immunol; 2019 Dec; 57():101209. PubMed ID: 31207283
[TBL] [Abstract][Full Text] [Related]
5. T-cell-depleted haploidentical stem cell transplantation results improve with time in adults with acute leukemia: A study from the Acute Leukemia Working Party of the European Society of Blood and Marrow Transplantation (EBMT).
Sestili S; Labopin M; Ruggeri A; Velardi A; Ciceri F; Maertens J; Kanz L; Aversa F; Lewalle P; Bunjes D; Mohty M; Nagler A
Cancer; 2018 May; 124(10):2142-2150. PubMed ID: 29469924
[TBL] [Abstract][Full Text] [Related]
6. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection.
Hale G; Zhang MJ; Bunjes D; Prentice HG; Spence D; Horowitz MM; Barrett AJ; Waldmann H
Blood; 1998 Dec; 92(12):4581-90. PubMed ID: 9845524
[TBL] [Abstract][Full Text] [Related]
7. Timing of Alemtuzumab With Respect to Day of Bone Marrow Infusion and its Effects Upon Engraftment and Graft-Versus-Host Disease in Patients With Sickle Cell Disease: A Single-Institutional Study.
Sahdev I; Brochstein J; Werther N; Stiles J
J Pediatr Hematol Oncol; 2020 Nov; 42(8):e718-e722. PubMed ID: 32890079
[TBL] [Abstract][Full Text] [Related]
8. An intermediate alemtuzumab schedule reduces the incidence of mixed chimerism following reduced-intensity conditioning hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis.
Marsh RA; Kim MO; Liu C; Bellman D; Hart L; Grimley M; Kumar A; Jodele S; Myers KC; Chandra S; Leemhuis T; Mehta PA; Bleesing JJ; Davies SM; Jordan MB; Filipovich AH
Biol Blood Marrow Transplant; 2013 Nov; 19(11):1625-31. PubMed ID: 24035782
[TBL] [Abstract][Full Text] [Related]
9. TcRαβ-depleted haploidentical transplantation results in adult acute leukemia patients.
Kaynar L; Demir K; Turak EE; Öztürk ÇP; Zararsız G; Gönen ZB; Gökahmetoğlu S; Şıvgın S; Eser B; Köker Y; Solmaz M; Ünal A; Çetin M
Hematology; 2017 Apr; 22(3):136-144. PubMed ID: 27724812
[TBL] [Abstract][Full Text] [Related]
10. T-cell depleting antibodies: new hope for induction of allograft tolerance in bone marrow transplantation?
Simpson D
BioDrugs; 2003; 17(3):147-54. PubMed ID: 12749751
[TBL] [Abstract][Full Text] [Related]
11. HLA-haploidentical stem cell transplantation in children with inherited bone marrow failure syndromes: A retrospective analysis on behalf of EBMT severe aplastic Anemia and pediatric diseases working parties.
Giardino S; Eikema DJ; Piepenbroek B; Algeri M; Ayas M; Faraci M; Tbakhi A; Zecca M; Essa M; Neven B; Bertrand Y; Kharya G; Bykova T; Lawson S; Petrini M; Mohseny A; Rialland F; James B; Colita A; Fahd M; Cesaro S; Schulz A; Kleinschmidt K; Kałwak K; Corbacioglu S; Dufour C; Risitano A; de Latour RP
Am J Hematol; 2024 Jun; 99(6):1066-1076. PubMed ID: 38497679
[TBL] [Abstract][Full Text] [Related]
12. Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitution.
Klangsinsirikul P; Carter GI; Byrne JL; Hale G; Russell NH
Blood; 2002 Apr; 99(7):2586-91. PubMed ID: 11895797
[TBL] [Abstract][Full Text] [Related]
13. Alemtuzumab levels impact acute GVHD, mixed chimerism, and lymphocyte recovery following alemtuzumab, fludarabine, and melphalan RIC HCT.
Marsh RA; Lane A; Mehta PA; Neumeier L; Jodele S; Davies SM; Filipovich AH
Blood; 2016 Jan; 127(4):503-12. PubMed ID: 26644451
[TBL] [Abstract][Full Text] [Related]
14. Unrelated donor hematopoietic stem cell transplantation for the treatment of non-malignant genetic diseases: An alemtuzumab based regimen is associated with cure of clinical disease; earlier clearance of alemtuzumab may be associated with graft rejection.
Abdel-Azim H; Mahadeo KM; Zhao Q; Khazal S; Kohn DB; Crooks GM; Shah AJ; Kapoor N
Am J Hematol; 2015 Nov; 90(11):1021-6. PubMed ID: 26242764
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo T-cell depletion with myeloablative or reduced-intensity conditioning in pediatric hematopoietic stem cell transplantation.
Seidel MG; Fritsch G; Matthes-Martin S; Lawitschka A; Lion T; Pötschger U; Rosenmayr A; Fischer G; Gadner H; Peters C
Haematologica; 2005 Oct; 90(10):1405-14. PubMed ID: 16219578
[TBL] [Abstract][Full Text] [Related]
16. Successful engraftment of T-cell-depleted haploidentical "three-loci" incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum.
Aversa F; Tabilio A; Terenzi A; Velardi A; Falzetti F; Giannoni C; Iacucci R; Zei T; Martelli MP; Gambelunghe C
Blood; 1994 Dec; 84(11):3948-55. PubMed ID: 7524753
[TBL] [Abstract][Full Text] [Related]
17. Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence.
van Besien K; Dew A; Lin S; Joseph L; Godley LA; Larson RA; Odenike T; Rich E; Stock W; Wickrema A; Artz AS
Leuk Lymphoma; 2009 Nov; 50(11):1809-17. PubMed ID: 19821799
[TBL] [Abstract][Full Text] [Related]
18. Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease, Stem Cell Source, and Alemtuzumab Regimen.
Marsh RA; Rao MB; Gefen A; Bellman D; Mehta PA; Khandelwal P; Chandra S; Jodele S; Myers KC; Grimley M; Dandoy C; El-Bietar J; Kumar AR; Leemhuis T; Zhang K; Bleesing JJ; Jordan MB; Filipovich AH; Davies SM
Biol Blood Marrow Transplant; 2015 Aug; 21(8):1460-70. PubMed ID: 25865646
[TBL] [Abstract][Full Text] [Related]
19. Alemtuzumab clearance, lymphocyte count, and T-cell chimerism after hematopoietic stem cell transplant in sickle cell disease.
Furstenau D; Peer CJ; Hughes TE; Uchida N; Tisdale J; Hall OM; Figg WD; Hsieh M
Pharmacotherapy; 2022 Jan; 42(1):14-22. PubMed ID: 34669981
[TBL] [Abstract][Full Text] [Related]
20. Haploidentical transplantation using low-dose alemtuzumab: Comparison with haploidentical transplantation using low-dose thymoglobulin.
Kako S; Gomyo A; Akahoshi Y; Harada N; Kameda K; Ugai T; Wada H; Ishihara Y; Kawamura K; Sakamoto K; Sato M; Terasako-Saito K; Kimura SI; Kikuchi M; Nakasone H; Kanda J; Kanda Y
Eur J Haematol; 2019 Mar; 102(3):256-264. PubMed ID: 30578673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
